Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease
Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
This study aims to assess the safety and tolerability of AMG 609 when administered
subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD)
and to assess change in liver fat (expansion cohort only).